

Supplementary Information

Synthesis of 3-(Aminomethyl)pyridine by Traceless C3-Selective Umpolung of 1-Amidopyridin-1-ium Salts

Pingsheng Tang^{a,b}, Dehai Xiao^{*,a}, Bo Wang^{*,a}

^aKey Lab of Synthetic Polymer of the Chinese Academy of Sciences, Green Chemistry and Process Laboratory, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, P. R. China.

^bUniversity of Chinese Academy of Sciences, Beijing 100049, P. R. China.

*E-mail: wangbo@ciac.ac.cn; dhxiao@ciac.ac.cn

Contents


General information	2
Synthesis and characterization data	2-9
References	9
¹ H NMR and ¹³ C NMR spectra of products	10-37
HPLC-HRMS spectrum of reaction mixture (experiment entry 8, Table 2 in main text)	38-39
References on the total synthesis of huperzine A	40

General information

Unless otherwise mentioned, all reactions were carried out under anhydrous conditions, and all commercially available reagents were used as received. 1-amidopyridin-1-ium salts¹ and amins² were synthesized according to literature reports. Anhydrous solvents were obtained from a Pure Solvent purification system from Innovative Technology. Reactions were monitored by thin layer chromatography (TLC) carried out on S-2 0.25 mm E. Merck silica gel plates (60 F₂₅₄) and visualized by UV fluorescence (254 nm) and one of the following: phosphomolybdic acid, ninhydrin, *p*-anisaldehyde. Column chromatography was performed over Silicycle P₆₀ silica gel (230–400 mesh). NMR spectra were recorded on Bruker AVANCE III 300, AVANCE III 400 and AVANCE III HD500 instruments using residual CHCl₃ as internal references ($\delta_{\text{H}} = 7.26$ ppm and $\delta_{\text{C}} = 77.16$ ppm). The following abbreviations were used to designate multiplicities: s (singlet), d (doublet), t (triplet), q (quartet), hept (heptet), m (multiplet), br (broad). High resolution mass spectra (HRMS) were recorded on a Bruker micrOTOF-QII mass spectrometer using electrospray ionization. Melting points were recorded on a WRS-1B melt point apparatus (Shanghai Shengguang Instrument Co., LTD) and were uncorrected.


Synthesis and characterization data

General procedure for reaction conditions optimization




To a solution of 1-amidopyridin-1-ium iodide **1a to 1f** (0.2 mmol) in designated solvent (1.0 mL) was added designated amount of amins **2a**, and the mixture was stirred at designated temperature and monitored by TLC till **1a to 1f** disappeared. The mixture was cooled to room temperature, and zinc powder (130.8 mg, 2.0 mmol) and glacial acetic acid (1.0 mL) were added and stirred for 5 min. The reaction was quenched with saturated NaHCO₃ solution and extracted with CH₂Cl₂. The combined organic extracts were washed with brine, dried over anhydrous MgSO₄ and concentrated under reduced pressure. The residue was purified by flash chromatography using CH₂Cl₂/MeOH to give product **3a**.


General procedure for synthesis of pyridine **3b to 3w**




To a solution of 1-amidopyridin-1-ium iodide **1f** (76.8 mg, 0.2 mmol) in CH₃CN (1.0 mL) was added aminational **2b** to **2w** (0.44 mmol), and the mixture was stirred in a 90 °C oil bath, and monitored by TLC till **1f** disappeared. The mixture was cooled to room temperature, and zinc powder (130.8 mg, 2.0 mmol) and glacial acetic acid (1.0 mL) were added and stirred for 5 min. The reaction was quenched with saturated NaHCO₃ solution and extracted with CH₂Cl₂. The combined organic extracts was washed with brine, dried over anhydrous MgSO₄ and concentrated under reduced pressure. The residue was purified by flash chromatography using CH₂Cl₂/MeOH to give products **3b** to **3w**.




4-(phenyl(pyridine-3-yl)methyl)morpholine (**3a**): 45.6 mg (90% yield), white solid, m.p. 102 – 104 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.64 (d, *J* = 2.2 Hz, 1H), 8.41 (dd, *J* = 4.8, 1.7 Hz, 1H), 7.72 (ddd, *J* = 7.9, 2.0 Hz, 1H), 7.43 – 7.33 (m, 2H), 7.32 – 7.22 (m, 2H), 7.22 – 7.13 (m, 2H), 4.23 (s, 1H), 3.68 (t, *J* = 4.7 Hz, 4H), 2.36 (m, 4H). ¹³C NMR (75 MHz, CDCl₃) δ 149.8, 148.8, 141.3, 137.9, 135.5, 128.9, 128.0, 127.6, 123.7, 74.3, 67.2, 52.7. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₆H₁₉N₂O 255.1492; Found 255.1500.




4-((4-methoxyphenyl)(pyridine-3-yl)methyl)morpholine (**3b**): 43.7 mg (77% yield), white solid, m.p. 109 – 110 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.64 (s, 1H), 8.42 (d, *J* = 3.9 Hz, 1H), 7.73 (d, *J* = 7.9 Hz, 1H), 7.28 (d, *J* = 8.7 Hz, 2H), 7.20 (dd, *J* = 7.8, 4.8 Hz, 1H), 6.82 (d, *J* = 8.7 Hz, 2H), 4.20 (s, 1H), 3.74 (s, 3H), 3.69 (t, *J* = 4.6 Hz, 4H), 2.45 – 2.28 (m, 4H). ¹³C NMR (100 MHz, CDCl₃) δ 159.0, 149.5, 148.5, 138.3, 135.4, 133.2, 129.1, 123.7, 114.2, 73.5, 67.1, 55.3, 52.6. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₇H₂₁N₂O₂ 285.1598; Found 285.1604.




4-(pyridin-3-yl(*p*-tolyl)methyl)morpholine (**3c**): 46.8 mg (87% yield), white solid, m.p. 106 – 108 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.66 (d, *J* = 1.5 Hz, 1H), 8.42 (dd, *J* = 4.7, 1.3 Hz, 1H), 7.74 (ddd, *J* = 7.8, 1.8 Hz, 1H), 7.27 (d, *J* = 7.9 Hz, 2H), 7.19 (dd, *J* = 7.9, 4.8 Hz, 1H), 7.09 (d, *J* = 7.9 Hz, 2H), 4.22 (s, 1H), 3.70 (t, *J* = 4.7 Hz, 4H), 2.36 (m, 4H), 2.28 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 149.6, 148.6, 138.2, 138.1, 137.3, 135.4, 129.6, 127.9, 123.7, 74.0, 67.1, 52.6, 21.1. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₇H₂₁N₂O 269.1648; Found 269.1653.




4-((2-fluorophenyl)(pyridin-3-yl)methyl)morpholine (**3d**): 49.6 mg (91% yield), white solid, m.p. 113 – 114 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.67 (d, *J* = 1.2 Hz, 1H), 8.44 (dd, *J* = 4.7, 1.4 Hz, 1H), 7.73 (d, *J* = 7.9 Hz, 1H), 7.57 (ddd, *J* = 7.4, 1.9 Hz, 1H), 7.24 – 7.06 (m, 3H), 6.97 (ddd, *J* = 9.5, 8.0, 1.3 Hz, 1H), 4.71 (s, 1H), 3.70 (t, *J* = 4.7 Hz, 4H), 2.41 (m, 4H). ¹³C NMR (100 MHz, CDCl₃) δ 160.7 (d, ¹*J*(C-F) = 246.4 Hz), 149.9, 148.7, 136.8, 135.8, 128.9 (d, ³*J*(C-F) = 8.4 Hz), 128.7 (d, ³*J*(C-F) = 3.8 Hz), 128.0 (d, ²*J*(C-F) = 12.5 Hz), 124.6 (d, ³*J*(C-F) = 3.5 Hz), 123.7, 115.8 (d, ²*J*(C-F) = 22.4 Hz), 67.1, 65.1 (d, ⁴*J*(C-F) = 2.1 Hz), 52.4. HRMS (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₆H₁₈FN₂O 273.1398; Found 273.1406.




4-((4-chlorophenyl)(pyridin-3-yl)methyl)morpholine (**3e**): 46.1 mg (80% yield), white solid, m.p. 118 – 120 °C. **¹H NMR** (300 MHz, CDCl₃) δ 8.62 (d, *J* = 1.6 Hz, 1H), 8.44 (dd, *J* = 4.7, 1.4 Hz, 1H), 7.69 (dd, *J* = 7.9, 1.8 Hz, 1H), 7.33 (d, *J* = 8.5 Hz, 2H), 7.25 (d, *J* = 8.5 Hz, 2H), 7.20 (dd, *J* = 7.9, 4.9 Hz, 1H), 4.23 (s, 1 H), 3.69 (t, *J* = 4.6 Hz, 4H), 2.36 (m, *J* = 7.3 Hz, 4H). **¹³C NMR** (100 MHz, CDCl₃) δ 149.5, 148.9, 139.7, 137.3, 135.5, 133.3, 129.3, 129.1, 123.8, 73.5, 67.0, 52.5. **HRMS** (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₆H₁₈ClN₂O 289.1102; Found 289.1109.




4-((3-bromophenyl)(pyridin-3-yl)methyl)morpholine (**3f**): 57.5 mg (86% yield), white solid, m.p. 127 – 128 °C. **¹H NMR** (300 MHz, CDCl₃) δ 8.62 (d, *J* = 1.7 Hz, 1H), 8.45 (dd, *J* = 4.7, 1.4 Hz, 1H), 7.70 (ddd, *J* = 7.9, 1.7 Hz, 1H), 7.55 (dd, 1H), 7.34 (d, *J* = 1.4 Hz, 1H), 7.31 (d, *J* = 1.6 Hz, 1H), 7.21 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.15 (dd, *J* = 8.1, 7.5 Hz, 1H), 4.21 (s, 1H), 3.70 (t, *J* = 4.6 Hz, 4H), 2.53 – 2.18 (m, *J* = 4.4 Hz, 4H). **¹³C NMR** (100 MHz, CDCl₃) δ 149.6, 149.0, 143.7, 137.1, 135.6, 130.8, 130.8, 130.6, 126.6, 123.8, 123.0, 73.7, 67.0, 52.6. **HRMS** (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₆H₁₈BrN₂O 333.0597; Found 333.0604.




4-((2-bromophenyl)(pyridin-3-yl)methyl)morpholine (**3g**): 61.5 mg (92% yield), white solid, m.p. 132 – 133 °C. **¹H NMR** (300 MHz, CDCl₃) δ 8.74 (d, *J* = 1.7 Hz, 1H), 8.44 (dd, *J* = 4.7, 1.5 Hz, 1H), 7.77 (ddd, *J* = 8.1, 1.7 Hz, 2H), 7.49 (dd, *J* = 8.0, 1.1 Hz, 1H), 7.32 (ddd, *J* = 8.1, 7.2, 0.9 Hz, 1H), 7.20 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.06 (ddd, *J* = 7.8, 1.5 Hz, 1H), 4.83 (s, 1H), 3.69 (t, *J* = 4.7 Hz, 4H), 2.55 – 2.40 (m, 2H), 2.40 – 2.28 (m, 2H). **¹³C NMR** (100 MHz, CDCl₃) δ 150.3, 148.8, 140.1, 136.2, 136.1, 133.4, 129.3, 128.9, 128.1, 124.6, 123.6, 71.2, 67.1, 52.6. **HRMS** (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₆H₁₈BrN₂O 333.0597; Found 333.0600.




4-(morpholino(pyridin-3-yl)methyl)benzonitrile (**3h**): 47.1 mg (84% yield), white solid, m.p. 143 – 145 °C. **¹H NMR** (300 MHz, CDCl₃) δ 8.59 (d, *J* = 1.8 Hz, 1H), 8.44 (d, *J* = 4.5, 1.2 Hz, 1H), 7.67 (ddd, *J* = 7.8, 1.8 Hz, 1H), 7.58 (d, *J* = 8.5 Hz, 2H), 7.53 (d, *J* = 8.5 Hz, 2H), 7.22 (dd, *J* = 7.8, 4.8 Hz, 1H), 4.31 (s, 1H), 3.69 (m, 4H), 2.35 (m, 4H). **¹³C NMR** (100 MHz, CDCl₃) δ 149.5, 149.2, 146.8, 136.4, 135.6, 132.8, 128.6, 123.9, 118.6, 111.5, 73.7, 66.9, 52.5. **HRMS** (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₇H₁₈N₃O 280.1444; Found 280.1452.




methyl 4-(morpholino(pyridin-3-yl)methyl)benzoate (**3i**): 49.5 mg (79% yield), white solid, m.p. 91 – 92 °C. **¹H NMR** (300 MHz, CDCl₃) δ 8.63 (d, *J* = 1.5 Hz, 1H), 8.44 (dd, *J* = 4.5, 1.2 Hz, 1H), 7.95 (d, *J* = 8.3 Hz, 2H), 7.71 (ddd, *J* = 8.1, 1.8, 1.5 Hz, 1H), 7.48 (d, *J* = 8.3 Hz, 2H), 7.20 (dd, *J* = 7.8, 4.8 Hz, 1H), 4.31 (s, 1H), 3.86 (s, 3H), 3.70 (t, *J* = 4.6 Hz, 4H), 2.37 (m, *J* = 4.3 Hz, 4H). **¹³C NMR** (100 MHz, CDCl₃) δ 166.7, 149.6, 149.0, 146.4, 137.0, 135.6, 130.3, 129.5, 127.9, 123.8, 73.9, 67.0, 52.5, 52.2. **HRMS** (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₈H₂₁N₂O₃ 313.1547; Found 313.1554.




4-((1-bromonaphthalen-2-yl)(pyridin-3-yl)methyl)morpholine (**3j**): 71.2 mg (93% yield), white solid, m.p. 159 – 160 °C. **¹H NMR** (300 MHz, CDCl₃) δ 8.87 (d, *J* = 1.8 Hz, 1H), 8.45 (dd, *J* = 4.8, 1.5 Hz, 1H), 8.29 (d, *J* = 8.4 Hz, 1H), 7.92 (d, *J* = 8.7 Hz, 1H), 7.86 (ddd, *J* = 7.8, 1.8 Hz, 1H), 7.83 – 7.72 (m, 2H), 7.61 – 7.44 (m, 2H), 7.20 (dd, *J* = 7.8, 4.8 Hz, 1H), 5.22 (s, 1H), 3.80 – 3.60 (m, 4H), 2.60 – 2.36 (m, 4H). **¹³C NMR** (75 MHz, CDCl₃) δ 150.2, 148.9, 138.2, 136.4, 135.9, 133.9, 132.6, 128.5, 128.1, 127.8, 127.7, 126.9, 125.8, 124.6, 123.6, 71.9, 67.1, 52.6. **HRMS** (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₀H₂₀BrN₂O 383.0754; Found 383.0754.




4-(pyridin-3-yl(pyridin-4-yl)methyl)morpholine (**3k**): 88.0 mg (69% yield), white solid, m.p. 90 – 92 °C. **¹H NMR** (300 MHz, CDCl₃) δ 8.59 (d, *J* = 1.5 Hz, 1H), 8.49 (d, *J* = 5.7 Hz, 2H), 8.47 – 8.38 (m, 1H), 7.65 (d, *J* = 7.9 Hz, 1H), 7.32 (d, *J* = 5.7 Hz, 2H), 7.20 (dd, *J* = 7.9, 4.8 Hz, 1H), 4.23 (s, 1H), 3.67 (t, *J* = 4.6 Hz, 4H), 2.34 (q, *J* = 4.6 Hz, 4H). **¹³C NMR** (75 MHz, CDCl₃) δ 150.4, 150.2, 149.6, 149.3, 135.9, 135.5, 123.8, 122.9, 73.1, 66.9, 52.3. **HRMS** (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₅H₁₈N₃O 256.1444; Found 256.1441.




4-(phenyl(pyridin-3-yl)methyl)thiomorpholine (**3l**): 126.8 mg (94% yield), white solid, m.p. 86 – 88 °C. **¹H NMR** (300 MHz, CDCl₃) δ 8.61 (s, 1H), 8.44 (d, *J* = 4.8 Hz, 1H), 7.68 (d, *J* = 7.9 Hz, 1H), 7.40 – 7.15 (m, 6H), 4.44 (s, 1H), 2.67 (s, 8H). **¹³C NMR** (75 MHz, CDCl₃) δ 149.6, 148.5, 140.8, 137.6, 135.4, 128.7, 128.0, 127.4, 123.5, 73.4, 53.5, 28.1. **HRMS** (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₆H₁₉N₂S 271.1264; Found 271.1267.




1-methyl-4-(phenyl(pyridin-3-yl)methyl)piperazine (**3m**): 119.2 mg (89% yield), white solid, m.p. 105 – 107 °C. **¹H NMR** (300 MHz, CDCl₃) δ 8.65 (d, *J* = 2.2 Hz, 1H), 8.42 (dd, *J* = 4.8, 1.7 Hz, 1H), 7.71 (ddd, *J* = 7.9, 2.0 Hz, 1H), 7.46 – 7.32 (m, 2H), 7.33 – 7.23 (m, 2H), 7.22 – 7.09 (m, 2H), 4.27 (br s, 1H), 2.46 (s, 8H), 2.29 (s, 3H). **¹³C NMR** (75 MHz, CDCl₃) δ 149.6, 148.5, 141.6, 138.2, 135.4, 128.8, 127.9, 127.4, 123.6, 73.7, 55.3, 51.7, 45.8. **HRMS** (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₇H₂₂N₃ 268.1808; Found 268.1812.




3-(phenyl(piperidin-1-yl)methyl)pyridine (**3n**): 75.1 mg (60% yield), white solid, m.p. 87 – 88 °C. **¹H NMR** (300 MHz, CDCl₃) δ 8.63 (d, *J* = 2.2 Hz, 1H), 8.43 (dd, *J* = 4.8, 1.7 Hz, 1H), 7.72 (d, *J* = 7.9 Hz, 1H), 7.37 (m, 2H), 7.30 (m, 2H), 7.20 (m, 2H), 4.29 (s, 1H), 2.30 (m, 4H), 1.57 (m, 4H), 1.44 (m, 2H). **¹³C NMR** (75 MHz, CDCl₃) δ 149.7, 148.3, 142.0, 138.7, 135.5, 128.6, 128.0, 127.2, 123.5, 74.2, 53.1, 26.2, 24.6. **HRMS** (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₇H₂₁N₂ 253.1699; Found 253.1701.




N,N-dimethyl-1-phenyl-1-(pyridin-3-yl)methanamine (**3o**): 58.6 mg (55% yield), white solid, m.p. 82–84 °C. **¹H NMR** (300 MHz, CDCl₃) δ 8.65 (d, *J* = 2.4 Hz, 1H), 8.44 (dd, *J* = 4.8, 1.5 Hz, 1H), 7.76 (ddd, *J* = 7.8, 2.0 Hz, 1H), 7.40 (m, 2H), 7.30 (m, 2H), 7.20 (m, 2H), 4.13 (s, 1H), 2.20 (s, 6H). **¹³C NMR** (75 MHz, CDCl₃) δ 149.6, 148.5, 142.4, 138.9, 135.2, 128.8, 127.8, 127.4, 123.6, 75.4, 44.6. **HRMS** (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₄H₁₇N₂ 213.1386; Found 213.1389.




N-benzyl-*N*-methyl-1-phenyl-1-(pyridin-3-yl)methanamine (**3p**): 114.2 mg (79% yield), white solid, m.p. 119 – 121 °C. **¹H NMR** (300 MHz, CDCl₃) δ 8.73 (d, *J* = 2.2 Hz, 1H), 8.45 (dd, *J* = 4.8, 1.7 Hz, 1H), 7.84 (ddd, *J* = 7.9, 2.0 Hz, 1H), 7.58 – 7.18 (m, 11H), 4.56 (s, 1H), 3.57 (d, *J* = 13.5 Hz, 1H), 3.47 (d, *J* = 13.5 Hz, 1H), 2.10 (s, 3H). **¹³C NMR** (75 MHz, CDCl₃) δ 149.8, 148.5, 141.7, 139.4, 138.4, 135.6, 128.8, 128.6, 128.4, 128.1, 127.5, 127.0, 123.6, 72.7, 59.7, 40.2. **HRMS** (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₀H₂₁N₂ 289.1699; Found 289.1703.




N,N-dibenzyl-1-phenyl-1-(pyridin-3-yl)methanamine (**3q**): 40.9 mg (22% yield), white solid, m.p. 166 – 168 °C. **¹H NMR** (300 MHz, CDCl₃) δ 8.72 (s, 1H), 8.54 (d, *J* = 2.7 Hz, 1H), 7.73 (d, *J* = 7.9 Hz, 1H), 7.54 – 7.14 (m, 16H), 5.04 (s, 1H), 3.59 (d, *J* = 14.1 Hz, 2H), 3.58 (d, *J* = 14.1 Hz, 2H). **¹³C NMR** (75 MHz, CDCl₃) δ 150.8, 148.6, 139.2, 138.9, 136.7, 136.0, 129.3, 128.7, 128.6, 128.5, 127.6, 127.2, 123.2, 65.1, 53.9. **HRMS** (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₆H₂₅N₂ 365.2012; Found 365.2014.




4-(pyridin-3-ylmethyl)morpholine (**3r**): 22.0 mg (25% yield), pale yellow oil. **¹H NMR** (300 MHz, CDCl₃) δ 8.52 (d, *J* = 1.5 Hz, 1H), 8.48 (dd, *J* = 4.7, 1.3 Hz, 1H), 7.66 (ddd, *J* = 7.8 Hz, 1H), 7.23 (dd, *J* = 7.8, 5.0 Hz, 1H), 3.68 (m, 4H), 3.48 (s, 2H), 2.42 (m, 4H). **¹³C NMR** (100 MHz, CDCl₃) δ 150.6, 148.8, 136.9, 133.3, 123.5, 67.0, 60.7, 53.6. **HRMS** (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₀H₁₅N₂O 179.1179; Found 179.1182.




3,5-bis(morpholinomethyl)pyridine (**3r'**): 90.6 mg (65% yield), pale yellow oil. **¹H NMR** (300 MHz, CDCl₃) δ 8.40 (d, *J* = 2.1 Hz, 2H), 7.61 (dd, *J* = 2.2 Hz, 1H), 3.66 (m, 8H), 3.47 (s, 4H), 2.40 (m, 8H). **¹³C NMR** (100 MHz, CDCl₃) δ 149.3, 137.4, 132.8, 66.8, 60.4, 53.4. **HRMS** (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₁₅H₂₄N₃O₂ 278.1863; Found 278.1866.



1,1'-(pyridine-3,5-diyl)bis(*N,N*-dibenzylmethanamine) (**3s**): 212.5 mg (85% yield), pale yellow solid, m.p. 146 – 148 °C. **¹H NMR** (300 MHz, CDCl₃) δ 8.47 (br s, 2H), 7.86 (s, 1H), 7.49 – 7.22 (m, 20H), 3.59 (s, 8H), 3.58 (s, 4H). **¹³C NMR** (75 MHz, CDCl₃) δ 149.0, 139.4, 136.7, 134.9, 128.8, 128.4, 127.2, 58.2, 55.2. **HRMS** (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₃₅H₃₆N₃ 498.2904; Found 498.2909.





1,1'-(pyridine-3,5-diyl)bis(*N*-benzyl-*N*-methylmethanamine) (**3t**): 143.3 mg (83% yield), pale yellow solid, m.p. 121 – 124 °C. **¹H NMR** (300 MHz, CDCl₃) δ 8.49 (d, *J* = 2.1 Hz, 2H), 7.74 (d, *J* = 2.1 Hz, 1H), 7.51 – 7.02 (m, 10H), 3.55 (s, 4H), 3.54 (s, 4H), 2.21 (s, 6H). **¹³C NMR** (75 MHz, CDCl₃) δ 149.1, 138.9, 137.0, 134.3, 128.9, 128.3, 127.1, 61.9, 58.9, 42.2. **HRMS** (ESI-TOF) *m/z*: [M + H]⁺ Calcd for C₂₃H₂₈N₃ 346.2278; Found 346.2284.




N,N'-(pyridine-3,5-diylbis(methylene))bis(*N*-butylbutan-1-amine) (**3u**): 57.0 mg (32% yield), pale yellow oil. **¹H NMR** (300 MHz, CDCl₃) δ 8.37 (d, *J* = 2.1 Hz, 2H), 7.60 (s, 1H), 3.51 (s, 4H), 2.48 – 2.23 (t, *J* = 7.2 Hz, 8H), 1.50 – 1.34 (m, 8H), 1.34 – 1.17 (m, 8H), 0.84 (t, *J* = 7.3 Hz, 12H). **¹³C NMR** (75 MHz, CDCl₃) δ 148.8, 137.1,

135.2, 55.9, 53.6, 29.4, 20.6, 14.2. **HRMS** (ESI-TOF) m/z : $[M + H]^+$ Calcd for $C_{23}H_{44}N_3$ 362.3530; Found 362.3535.

 *N,N'*-(pyridine-3,5-diylbis(methylene))bis(*N*-ethylethanamine) (**3v**): 82.3 mg (66% yield), pale yellow oil. **¹H NMR** (300 MHz, $CDCl_3$) δ 8.37 (s, 2H), 7.64 (s, 1H), 3.54 (s, 4H), 2.48 (q, $J = 7.1$ Hz, 8H), 0.99 (t, $J = 7.1$ Hz, 12H). **¹³C NMR** (75 MHz, $CDCl_3$) δ 149.1, 137.5, 134.4, 54.7, 46.8, 11.6. **HRMS** (ESI-TOF) m/z : $[M + H]^+$ Calcd for $C_{15}H_{28}N_3$ 250.2278; Found 250.2284.


 *N,N'*-(pyridine-3,5-diylbis(methylene))bis(*N*-methylpropan-2-amine) (**3w**): 75.5 mg (61% yield), pale yellow oil. **¹H NMR** (300 MHz, $CDCl_3$) δ 8.39 (s, 2H), 7.66 (s, 1H), 3.50 (s, 4H), 2.88 (hept, $J = 6.6$ Hz, 2H), 2.12 (s, 6H), 1.05 (d, $J = 6.6$ Hz, 12H). **¹³C NMR** (75 MHz, $CDCl_3$) δ 149.1, 137.2, 134.8, 54.8, 53.4, 36.8, 17.9. **HRMS** (ESI-TOF) m/z : $[M + H]^+$ Calcd for $C_{15}H_{28}N_3$ 250.2278; Found 250.2277.

Procedure for synthesis of 1-((*N*,4-dimethylphenyl)sulfonamido)-3-(morpholino(phenyl) methyl)pyridin-1-ium iodide



To a solution of 1-((*N*-methyltoluenesulfonamido)pyridin-1-ium iodide (39.4 mg, 0.1 mmol) in CH_2Cl_2 (2.0 mL) was added benzaldehyde (12.1 mg, 0.11 mmol) and morpholine (10.2 mg, 0.11 mmol). The mixture was stirred in a 50 °C oil bath for 18 h and then cooled to room temperature. The solvent was removed in vacuo and the residue was purified by gravity chromatography to give the titled product as yellow solid. 24.9 mg (44% yield), m.p. 142 – 143 °C. **¹H NMR** (300 MHz, $CDCl_3$) δ 8.99 (s, 1H), 8.85 (d, $J = 6.5$ Hz, 1H), 8.67 (d, $J = 8.1$ Hz, 1H), 8.19 (dd, $J = 8.0, 6.5$ Hz, 1H), 7.46 – 7.27 (m, 9H), 4.92 (s, 1H), 3.80 (s, 3H), 3.74 – 3.65 (m, 4H), 2.49 (s, 3H), 2.46 (s, 4H). **¹³C NMR** (75 MHz, $CDCl_3$) δ 148.3, 147.2, 145.9, 144.6, 143.8, 136.3, 131.3, 129.5, 129.5, 129.0, 128.9, 128.9, 126.9, 71.2, 66.9, 51.7, 40.2, 22.2. **HRMS** (ESI-TOF) m/z : $[M - I^-]^+$ Calcd for $C_{24}H_{28}N_3O_3S$ 438.1846; Found 438.1851.


Procedure for synthesis of *N*-ethyl-4-methoxy-*N*-(5-(phenylpyrrolidin-1-yl)methyl)-2-(pyrrolidin-1-yl)pyridin-1(2*H*)-yl)benzamide (**4**).



To a solution of **1f** (77.0 mg, 0.2 mmol) in CH_3CN (1.0 mL) was added amination **2x** (101.5 mg, 0.44 mmol). The mixture was stirred at room temperature for 1 h then a yellow precipitate was formed. The mixture was filtrated, washed with cold CH_3CN and dried in vacuo to give **4** as yellow powder (72.3 mg 74% yield). **¹H**


NMR (500 MHz, CDCl₃) δ 7.71 (d, J = 8.5 Hz, 2H), 7.37 (s, 1H), 7.21 – 7.02 (m, 5H), 6.89 (d, J = 8.5 Hz, 2H), 6.65 (d, J = 11.5 Hz, 1H), 6.34 – 6.19 (m, 2H), 4.37 (s, 1H), 4.10 (dq, 1H), 4.01 (dq, 1H), 3.83 (s, 3H), 3.27 (m, 4H), 2.40 (m, 2H), 2.33 (m, 2H), 1.99 – 1.89 (m, 4H), 1.73 (d, J = 6.5 Hz, 4H), 1.18 (t, J = 7.0 Hz, 3H). **¹³C NMR** (75 MHz, CDCl₃) δ 169.7, 160.7, 146.1, 144.4, 143.6, 138.9, 131.8, 129.0, 127.8, 126.2, 126.1, 112.7, 112.6, 98.0, 68.1, 55.5, 53.5, 49.3, 36.4, 25.5, 23.9, 11.9. **HRMS** (ESI-TOF) m/z : [M + H]⁺ Calcd for C₃₀H₃₉N₄O₂ 487.3068; Found 487.3063.

Procedure for synthesis of 3,5-bis(morpholinomethyl)pyridine 3s' from 1g




To a solution of **1g** (92.7 mg, 0.2 mmol) in CH₃CN (1.0 mL) was added aminal **2r** (82.2 mg, 0.44 mmol), and the mixture was stirred in a 90 °C oil bath for 4 h. The mixture was cooled to room temperature, and zinc powder (65.4 mg, 1.0 mmol) and glacial acetic acid (1.0 mL) were added and stirred for 5 min. The reaction was quenched with saturated NaHCO₃ solution and extracted with CH₂Cl₂. The combined organic extracts were washed with brine, dried over anhydrous MgSO₄ and concentrated under reduced pressure. The residue was purified by flash chromatography using CH₂Cl₂/MeOH to give products **3s'** as pale yellow oil (36.6 mg, 66% yield).

Procedure for synthesis of N-(5-bromo-2-morpholinopyridin-1(2H)-yl)-N-ethyl-4-methoxybenzamide (5)



To a solution of **1g** (92.6 mg, 0.2 mmol) in CH₃CN (1.0 mL) was added **2a** (115.5 mg, 0.44 mmol). The mixture was stirred at room temperature for 1 h, then the solvent was removed in vacuo and the residue was purified by flash chromatography to give **5** as yellow powder (71.4 mg, 85% yield). **¹H NMR** (300 MHz, CDCl₃) δ 7.95 (d, J = 8.9 Hz, 2H), 7.44 (s, 1H), 6.88 (d, J = 8.9 Hz, 2H), 6.74 (d, J = 10.6 Hz, 1H), 6.50 (d, J = 13.2 Hz, 1H), 5.59 (dd, J = 13.1, 10.7 Hz, 1H), 4.13 (q, J = 7.1 Hz, 2H), 3.84 (s, 3H), 3.78 – 3.65 (m, 4H), 3.23 – 3.12 (m, 4H), 1.22 (t, J = 7.2 Hz, 3H). **¹³C NMR** (75 MHz, CDCl₃) δ 168.9, 161.2, 147.4, 139.0, 138.5, 133.2, 126.9, 112.4, 111.2, 98.4, 66.2, 55.3, 48.5, 36.9, 11.3. **HRMS** (ESI-TOF) m/z : [M + H]⁺ Calcd for C₁₉H₂₅BrN₃O₃ 422.1074; Found 422.1071.

Procedure for synthesis of 1-(N-ethyl-4-methoxybenzamido)-3-(morpholino(phenyl)methyl) pyridin-1-ium iodide (7').





A solution of **1g** (92.9 mg, 0.2 mmol) and **2a** (115.5 mg, 0.44 mmol) in CH₃CN (1.0 mL) was stirred in a 90 °C oil bath for 30 min. The solvent was removed in vacuo and the residue was purified by gravity chromatography to give **7'** as yellow foam (88.5 mg, 79% yield). ¹H NMR (300 MHz, CDCl₃) δ 9.66 (d, *J* = 6.2 Hz, 1H), 9.56 (s, 1H), 8.74 (d, *J* = 8.1 Hz, 1H), 8.33 (dd, *J* = 7.2 Hz, 1H), 7.78 (d, *J* = 8.4 Hz, 2H), 7.48 – 7.18 (m, 5H), 6.91 (d, *J* = 8.4 Hz, 2H), 5.01 (s, 1H), 4.39 (q, *J* = 7.2 Hz, 2H), 3.81 (s, 3H), 3.77 – 3.57 (m, 4H), 2.49 (m, 2H), 2.35 (m, 2H), 1.21 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 169.4, 162.9, 146.8, 146.5, 145.9, 137.4, 130.9, 129.9, 129.5, 128.6, 128.4, 122.4, 114.3, 77.4, 70.7, 66.7, 55.6, 51.7, 50.8, 13.4. HRMS (ESI-TOF) *m/z*: [M – I]⁺ Calcd for C₂₆H₃₀N₃O₃⁺ 432.2282; Found 432.2280.


References

1. (a) C. Legault and A. B. Charette, *J. Org. Chem.*, 2003, **68**, 7119-7122; (b) M. A. de las Heras, A. Molina, J. J. Vaquero, J. L. Garcia Navio and J. Alvarez-Builla, *J. Org. Chem.*, 1993, **58**, 5862-5865.
2. (a) B. Hatano, K. Nagahashi and T. Kijima, *J. Org. Chem.*, 2008, **73**, 9188-9191; (b) Y. Zhou, Y. Xie, L. Yang, P. Xie and H. Huang, *Tetrahedron Lett.*, 2013, **54**, 2713-2716; (c) S. V. Lieberman, *J. Am. Chem. Soc.*, 1955, **77**, 1114-1116.


¹H NMR and ¹³C NMR spectra of products





¹³C NMR of **3a**, 75 MHz in CDCl₃




¹H NMR of **3b**, 300 MHz in CDCl₃




¹³C NMR of **3b**, 100 MHz in CDCl₃








¹H NMR of **3d**, 300 MHz in CDCl₃




¹³C NMR of **3d**, 100 MHz in CDCl₃







¹H NMR of **3f**, 300 MHz in CDCl₃




¹³C NMR of **3f**, 100 MHz in CDCl₃




¹H NMR of **3h**, 300 MHz in CDCl₃




¹³C NMR of **3h**, 100 MHz in CDCl₃




^1H NMR of **3i**, 300 MHz in CDCl_3




^{13}C NMR of **3i**, 100 MHz in CDCl_3




¹H NMR of **3j**, 300 MHz in CDCl₃




¹³C NMR of **3j**, 75 MHz in CDCl₃




¹H NMR of **3k**, 300 MHz in CDCl₃




¹³C NMR of **3k**, 75 MHz in CDCl₃




¹H NMR of **3l**, 300 MHz in CDCl₃




¹³C NMR of **3l**, 75 MHz in CDCl₃




¹H NMR of **3m**, 300 MHz in CDCl₃




¹³C NMR of **3m**, 75 MHz in CDCl₃




¹H NMR of **3n**, 300 MHz in CDCl₃




¹³C NMR of **3n**, 75 MHz in CDCl₃




¹H NMR of **3o**, 300 MHz in CDCl₃




¹³C NMR of **3o**, 75 MHz in CDCl₃




¹H NMR of **3p**, 300 MHz in CDCl₃




¹³C NMR of **3p**, 75 MHz in CDCl₃




¹H NMR of **3q**, 300 MHz in CDCl₃




¹³C NMR of **3q**, 75 MHz in CDCl₃




¹H NMR of **3r**, 300 MHz in CDCl₃




¹³C NMR of **3r**, 100 MHz in CDCl₃




^1H NMR of **3r'**, 300 MHz in CDCl_3




^{13}C NMR of **3r'**, 100 MHz in CDCl_3




¹H NMR of **3s**, 300 MHz in CDCl₃





¹³C NMR of **3s**, 75 MHz in CDCl₃




^1H NMR of **3t**, 300 MHz in CDCl_3




^{13}C NMR of **3t**, 75 MHz in CDCl_3







¹H NMR of **3v**, 300 MHz in CDCl₃





¹³C NMR of **3v**, 75 MHz in CDCl₃




¹H NMR of **3w**, 300 MHz in CDCl₃




¹³C NMR of **3w**, 75 MHz in CDCl₃







¹H NMR of 4, 500 MHz in CDCl₃





¹³C NMR of 4, 75 MHz in CDCl₃



¹H NMR of **5**, 300 MHz in CDCl₃



¹³C NMR of **5**, 75 MHz in CDCl₃



HPLC-HRMS spectrum of reaction mixture
(experiment entry 8, Table 2 in main text)





Generic Display Report

Analysis Info











Analysis Name D:\Data\tps\tps-xvi-107_41_01_9694.d
Method LC-MS3-HR-low.m
Sample Name tps-xvi-107
Comment

Acquisition Date 1/5/2017 6:49:29 PM

Operator NPS-LAB, CIAC
Instrument microTOF-Q II



Peak Assignment

Observed	Calculated	Cation	Formula	Assigned Structure
88.0754	88.0757	$[M + H]^+$	$C_4H_{10}NO^+$	
135.0445	135.0441	M^+	$C_8H_7O_2^+$	
168.0814	168.0808	M^+	$C_{12}H_{10}N^+$	
176.1076	176.1070	M^+	$C_{11}H_{14}NO^+$	
211.1237	211.1230	$[M + H]^+$	$C_{14}H_{15}N_2^+$	
237.1605	237.1598	M^+	$C_{13}H_{21}N_2O_2^+$	
257.1295	257.1285	M^+	$C_{15}H_{17}N_2O_2^+$	
298.1914	298.1914	M^+	$C_{18}H_{24}N_3O^+$	
344.1966	344.1969	$[M + H]^+$	$C_{19}H_{26}N_3O_3^+$	
347.1751				unknown
432.2267	432.2282	M^+	$C_{26}H_{30}N_3O_3^+$	

References on the total synthesis of huperzine A

- 1 L. G. Qian and R. Y. Ji, *Tetrahedron Lett.*, 1989, **30**, 2089-2090.
- 2 Y. Xia and A. P. Kozikowski, *J. Am. Chem. Soc.*, 1989, **111**, 4116-4117.
- 3 A. P. Kozikowski, F. Yamada, X. C. Tang and I. Hanin, *Tetrahedron Lett.*, 1990, **31**, 6159-6162.
- 4 A. P. Kozikowski, Y. Xia, E. R. Reddy, W. Tuckmantel, I. Hanin and X. C. Tang, *J. Org. Chem.*, 1991, **56**, 4636-4645.
- 5 S. Kaneko, T. Yoshino, T. Katoh and S. Terashima, *Heterocycles*, 1997, **46**, 27-30.
- 6 C. Chassaing, A. Haudrechy and Y. Langlois, *Tetrahedron Lett.*, 1999, **40**, 8805-8809.
- 7 A. Haudrechy, C. Chassaing, C. Riche and Y. Langlois, *Tetrahedron*, 2000, **56**, 3181-3187.
- 8 C. Lucey, S. A. Kelly and J. Mann, *Org Biomol Chem*, 2007, **5**, 301-306.
- 9 T. Koshiba, S. Yokoshima and T. Fukuyama, *Org. Lett.*, 2009, **11**, 5354-5356.
- 10 K. M. Maung, D. J. Wustmann and S. B. Herzon, *Chem Sci*, 2011, **2**, 2251-2253.
- 11 R. Ding, B. F. Sun and G. Q. Lin, *Org. Lett.*, 2012, **14**, 4446-4449.
- 12 J. D. White, Y. Li, J. Kim and M. Terinek, *Org. Lett.*, 2013, **15**, 882-885.
- 13 R. Ding, J. G. Fu, G. Q. Xu, B. F. Sun and G. Q. Lin, *J. Org. Chem.*, 2014, **79**, 240-250.
- 14 J. D. White, Y. Li, J. Kim and M. Terinek, *J. Org. Chem.*, 2015, **80**, 11806-11817.